First Time Loading...

Lyell Immunopharma Inc
NASDAQ:LYEL

Watchlist Manager
Lyell Immunopharma Inc Logo
Lyell Immunopharma Inc
NASDAQ:LYEL
Watchlist
Price: 2.3 USD -5.74% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. [ Read More ]

The intrinsic value of one LYEL stock under the Base Case scenario is 1.17 USD. Compared to the current market price of 2.3 USD, Lyell Immunopharma Inc is Overvalued by 49%.

Key Points:
LYEL Intrinsic Value
Base Case
1.17 USD
Overvaluation 49%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Lyell Immunopharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling LYEL stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Lyell Immunopharma Inc

Provide an overview of the primary business activities
of Lyell Immunopharma Inc.

What unique competitive advantages
does Lyell Immunopharma Inc hold over its rivals?

What risks and challenges
does Lyell Immunopharma Inc face in the near future?

Has there been any significant insider trading activity
in Lyell Immunopharma Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Lyell Immunopharma Inc.

Provide P/S
for Lyell Immunopharma Inc.

Provide P/E
for Lyell Immunopharma Inc.

Provide P/OCF
for Lyell Immunopharma Inc.

Provide P/FCFE
for Lyell Immunopharma Inc.

Provide P/B
for Lyell Immunopharma Inc.

Provide EV/S
for Lyell Immunopharma Inc.

Provide EV/GP
for Lyell Immunopharma Inc.

Provide EV/EBITDA
for Lyell Immunopharma Inc.

Provide EV/EBIT
for Lyell Immunopharma Inc.

Provide EV/OCF
for Lyell Immunopharma Inc.

Provide EV/FCFF
for Lyell Immunopharma Inc.

Provide EV/IC
for Lyell Immunopharma Inc.

Show me price targets
for Lyell Immunopharma Inc made by professional analysts.

What are the Revenue projections
for Lyell Immunopharma Inc?

How accurate were the past Revenue estimates
for Lyell Immunopharma Inc?

What are the Net Income projections
for Lyell Immunopharma Inc?

How accurate were the past Net Income estimates
for Lyell Immunopharma Inc?

What are the EPS projections
for Lyell Immunopharma Inc?

How accurate were the past EPS estimates
for Lyell Immunopharma Inc?

What are the EBIT projections
for Lyell Immunopharma Inc?

How accurate were the past EBIT estimates
for Lyell Immunopharma Inc?

Compare the revenue forecasts
for Lyell Immunopharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Lyell Immunopharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Lyell Immunopharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Lyell Immunopharma Inc compared to its peers.

Compare the P/E ratios
of Lyell Immunopharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Lyell Immunopharma Inc with its peers.

Analyze the financial leverage
of Lyell Immunopharma Inc compared to its main competitors.

Show all profitability ratios
for Lyell Immunopharma Inc.

Provide ROE
for Lyell Immunopharma Inc.

Provide ROA
for Lyell Immunopharma Inc.

Provide ROIC
for Lyell Immunopharma Inc.

Provide ROCE
for Lyell Immunopharma Inc.

Provide Gross Margin
for Lyell Immunopharma Inc.

Provide Operating Margin
for Lyell Immunopharma Inc.

Provide Net Margin
for Lyell Immunopharma Inc.

Provide FCF Margin
for Lyell Immunopharma Inc.

Show all solvency ratios
for Lyell Immunopharma Inc.

Provide D/E Ratio
for Lyell Immunopharma Inc.

Provide D/A Ratio
for Lyell Immunopharma Inc.

Provide Interest Coverage Ratio
for Lyell Immunopharma Inc.

Provide Altman Z-Score Ratio
for Lyell Immunopharma Inc.

Provide Quick Ratio
for Lyell Immunopharma Inc.

Provide Current Ratio
for Lyell Immunopharma Inc.

Provide Cash Ratio
for Lyell Immunopharma Inc.

What is the historical Revenue growth
over the last 5 years for Lyell Immunopharma Inc?

What is the historical Net Income growth
over the last 5 years for Lyell Immunopharma Inc?

What is the current Free Cash Flow
of Lyell Immunopharma Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Lyell Immunopharma Inc.

Financials

Balance Sheet Decomposition
Lyell Immunopharma Inc

Current Assets 554.7m
Cash & Short-Term Investments 546.2m
Other Current Assets 8.5m
Non-Current Assets 195.3m
Long-Term Investments 48.5m
PP&E 142.3m
Other Non-Current Assets 4.5m
Current Liabilities 34.5m
Accounts Payable 4.8m
Accrued Liabilities 28.1m
Other Current Liabilities 1.6m
Non-Current Liabilities 60.6m
Other Non-Current Liabilities 60.6m
Efficiency

Earnings Waterfall
Lyell Immunopharma Inc

Revenue
130k USD
Operating Expenses
-247.1m USD
Operating Income
-247m USD
Other Expenses
12.4m USD
Net Income
-234.6m USD

Free Cash Flow Analysis
Lyell Immunopharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

LYEL Profitability Score
Profitability Due Diligence

Lyell Immunopharma Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.

12/100
Profitability
Score

Lyell Immunopharma Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.

LYEL Solvency Score
Solvency Due Diligence

Lyell Immunopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Lyell Immunopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LYEL Price Targets Summary
Lyell Immunopharma Inc

Wall Street analysts forecast LYEL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LYEL is 6.12 USD with a low forecast of 4.04 USD and a high forecast of 9.45 USD.

Lowest
Price Target
4.04 USD
76% Upside
Average
Price Target
6.12 USD
166% Upside
Highest
Price Target
9.45 USD
311% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

LYEL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

LYEL Price
Lyell Immunopharma Inc

1M 1M
+20%
6M 6M
+47%
1Y 1Y
+19%
3Y 3Y
-86%
5Y 5Y
-86%
10Y 10Y
-86%
Annual Price Range
2.3
52w Low
1.39
52w High
3.86
Price Metrics
Average Annual Return -55.39%
Standard Deviation of Annual Returns 1.38%
Max Drawdown -92%
Shares Statistics
Market Capitalization 584.1m USD
Shares Outstanding 254 100 000
Percentage of Shares Shorted 10.15%

LYEL Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Lyell Immunopharma Inc Logo
Lyell Immunopharma Inc

Country

United States of America

Industry

Biotechnology

Market Cap

584.1m USD

Dividend Yield

0%

Description

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 219 full-time employees. The company went IPO on 2021-06-17. The firm offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. The company builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). The company offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. The company utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.

Contact

CALIFORNIA
South San Francisco
201 Haskins Way, Suite 301
+16506950677.0
https://lyell.com/

IPO

2021-06-17

Employees

219

Officers

Founder & Executive Chairman
Dr. Richard D. Klausner M.D.
President, CEO & Director
Dr. Lynn Seely M.D., Ph.D.
Chief Financial Officer
Mr. Charles W. Newton
Chief Operating Officer
Mr. Stephen J. Hill
Chief Scientific Officer
Dr. Gary Lee Ph.D.
Consultant
Ms. Elizabeth Homans
Show More
Founder & Scientific Advisor
Dr. Crystal L. Mackall M.D.
Director of Accounting
Nellie Dillery
Senior Vice President of Communications & Investor Relations
Ms. Ellen Rose
Show Less

See Also

Discover More
What is the Intrinsic Value of one LYEL stock?

The intrinsic value of one LYEL stock under the Base Case scenario is 1.17 USD.

Is LYEL stock undervalued or overvalued?

Compared to the current market price of 2.3 USD, Lyell Immunopharma Inc is Overvalued by 49%.